[-] Show simple item record

dc.contributor.authorChristiansen, Heathereng
dc.contributor.authorKraus, Connieeng
dc.date.issued2010-12eng
dc.description.abstractSativex?? (an oral-mucosal cannabinoid spray containing tetrahydrocannabinol and cannabidiol), as an adjuvant treatment, improves morning pain with movement and at rest, and sleep quality, with minimal adverse events, for patients with rheumatoid arthritis (RA) refractory to standard therapy. Morning stiffness was not significantly improved. (SOR: B, based on a single small RCT.) Sativex is not yet available in the United States.eng
dc.identifier.citationEvidence-based practice 13, no. 10 (2010): 22eng
dc.identifier.urihttp://hdl.handle.net/10355/9449eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionEvidence Based Practice, 2010eng
dc.relation.ispartofseriesEvidence-based practice 13, no. 10 (2010)eng
dc.relation.ispartofseriesSpotlight on pharmacy (Evidence-based practice, 2010)eng
dc.subjectpain controleng
dc.subject.lcshAnalgesiaeng
dc.titleAre cannabinoids safe and effective for treatment of patients with rheumatoid arthritis?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record